Company News
Arcus Biosciences Stock Falls 4% After Trial Halt
Arcus Biosciences shares dropped 4% after announcing the halt of its Phase 3 STAR-121 lung cancer trial due to futility.
The Independent Data Monitoring Committee recommended stopping the study after
